Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Cases of the Uveitis
4.2.2 Development of Novel Drugs and Treatments
4.3 Market Restraints
4.3.1 High Cost Associated with the Medications
4.3.2 Side Effect associated with Corticosteroid Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Corticosteroids
5.1.2 Cycloplegic Agents
5.1.3 Anti-TNF Agents
5.1.4 Immunosuppressants
5.2 By Distribution Channel
5.2.1 Hospitals Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Aldeyra Therapeutics, Inc.
6.1.3 Alimera Sciences Inc.,
6.1.4 Clearside Biomedical, Inc.
6.1.5 EyePoint Pharmaceuticals, Inc.
6.1.6 Novartis AG
6.1.7 Regeneron Pharmaceuticals
6.1.8 Bausch & Lomb Incorporated
6.1.9 Sirion Therapeutics, Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS